Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05065762 · ClinicalTrials.gov registry record

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

A clinical trial of Psoriasis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
232
Enrollment target
1
Study location

NCT05065762 is a study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 232 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05065762, a study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
232 participants
Enrollment target
1
Study location

Study Summary

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Conditions Studied

Study Locations (1)

North Carolina

  • Local Institution - Morrisville

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2021-10-01
Est. Completion 2022-02-07

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT05065762

The ClinicalTrials.gov registry entry for NCT05065762 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.

NCT05065762 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05065762 about?

NCT05065762 is a clinical study titled "Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment". The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

What is the current status of trial NCT05065762?

This trial is currently completed. The enrollment target is 232 participants. The study started on 2021-10-01. Estimated completion is 2022-02-07.

What conditions does trial NCT05065762 study?

This clinical trial studies the following conditions: Psoriasis.

Who is sponsoring clinical trial NCT05065762?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05065762 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.